← Back to Search

GLP-1 Receptor Agonist

Liraglutide for Insulin Resistance

Phase 4
Waitlist Available
Led By Peter D Reaven, MD
Research Sponsored by Phoenix VA Health Care System
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Age 40-75 years old
Body mass index (BMI) from 22 to 35 kg/m2
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks
Awards & highlights
Drug Has Already Been Approved
Pivotal Trial
All Individual Drugs Already Approved

Study Summary

In this research study, investigators will test the effects of an approved medication for diabetes,Liraglutide, to reduce insulin resistance that develops from eating a diet high in saturated fats.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Whole Body Insulin Sensitivity (insulin suppression test)
Secondary outcome measures
Adipose tissue arteriole function (vasodilation measurement)
Adipose tissue inflammation measures (e.g., interleukin (IL)-6, and -8, adiponectin, TNF-alpha, nuclear factor-kappa b, gene and protein expression)
Changes in adipose tissue insulin signaling pathway activation (compare insulin signaling pathway activity (e.g., Akt and insulin receptor phosphorylation)
+6 more

Side effects data

From 2017 Phase 4 trial • 100 Patients • NCT02014740
29%
nausea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Liraglutide
Metformin

Awards & Highlights

Drug Has Already Been Approved
The FDA has already approved this drug, and is just seeking more data.
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
All Individual Drugs Already Approved
Therapies where all constituent drugs have already been approved are likely to have better-understood side effect profiles.

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: LiraglutideExperimental Treatment1 Intervention
Liraglutide titration up to 1.8 mg/d over approximately 3 weeks
Group II: Sugar pillPlacebo Group1 Intervention
matching placebo and titration
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Liraglutide
FDA approved

Find a Location

Who is running the clinical trial?

Phoenix VA Health Care SystemLead Sponsor
12 Previous Clinical Trials
1,440 Total Patients Enrolled
1 Trials studying Insulin Resistance
300 Patients Enrolled for Insulin Resistance
Novo Nordisk A/SIndustry Sponsor
1,490 Previous Clinical Trials
2,381,237 Total Patients Enrolled
4 Trials studying Insulin Resistance
127 Patients Enrolled for Insulin Resistance
Peter D Reaven, MDPrincipal InvestigatorCarl T. Hayden Medical Research Foundation
5 Previous Clinical Trials
1,634 Total Patients Enrolled
1 Trials studying Insulin Resistance
300 Patients Enrolled for Insulin Resistance

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~3 spots leftby Feb 2025